Premium
Refractoriness to α‐interferon (Intron A) in previously chemotherapy‐treated patients with chronic myelocytic leukaemia
Author(s) -
Friche E.,
Hansen M. M.,
Wieslander S.
Publication year - 1988
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1988.tb00182.x
Subject(s) - medicine , chronic myeloid leukaemia , chemotherapy , interferon , peripheral blood , philadelphia chromosome , spleen , gastroenterology , immunology , biology , gene , chromosomal translocation , genetics
8 patients with chronic myeloid leukaemia in the chronic phase who had previously received chemotherapy were given α‐interferon (Intron A). The Intron A was administered subcutaneously at a dose of 2 × 10 6 I.U./m 2 three times a week and this was increased to 4–5 million I.U./m 2 daily if no response was obtained after 6–8 months. 1 patient was Philadelphia chromosome‐negative and was the only one who showed a major response to treatment. The other 7 patients never achieved haematologic remissions, or even a significant reduction in the immature blood leucocyte count or spleen size.